Tumor-targeted gene therapy: strategies for the preparation of ligand-polyethylene glycol-polyethylenimine/DNA complexes

被引:230
作者
Ogris, M
Walker, G
Blessing, T
Kircheis, R
Wolschek, M
Wagner, E
机构
[1] Univ Munich, Dept Pharm, D-81377 Munich, Germany
[2] Fac Pharm Montpellier, F-34060 Montpellier, France
[3] Igeneon AG, Immunotherapy Canc, A-1230 Vienna, Austria
[4] Univ Vienna, Dept Internal Med 4, Div Gastroenterol & Hepatol, A-1090 Vienna, Austria
关键词
cancer; gene therapy; non-viral vectors; PEGylation; receptor targeting;
D O I
10.1016/S0168-3659(03)00230-X
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Surface-shielded DNA delivery systems have been synthesized with virus-like characteristics that target gene expression into distant tumor tissues. Polyethylenimine (PEI)/DNA complexes ('polyplexes') conjugated with the cell-binding ligand transferrin (Tf) or epidermal growth factor (EGF) were used to achieve receptor-mediated endocytosis. The surface charge of the complexes was masked by covalently linking PEI to polyethylene glycol (PEG). Three alternatives for generating these surface-shielded formulations were utilized, attaching ligand and PEG molecules to PEI either before or after DNA complex formation. The stabilized formulations could be ultra-concentrated, stored frozen, and applied systemically after thawing. Intravenous injection of Tf-PEG-coated polyplexes resulted in gene transfer to subcutaneous Neuro2a neuroblastoma tumors of syngeneic A/J mice; EGF-PEG-coated polyplexes were intravenously applied for targeting human hepatocellular carcinoma xenografts in SCID mice. In these models, luciferase marker gene expression levels in tumor tissues were 10- to 100-fold higher than in other organ tissues. Repeated systemic application of Tf-PEG-PEI/DNA complexes encoding tumor necrosis factor alpha (TNF-alpha) into tumor-bearing mice induced tumor necrosis and inhibition of tumor growth in three murine tumor models of different tissue origin (Neuro2a, M-3 or B16 melanoma). (C) 2003 Elsevier B.V. All rights reserved.
引用
收藏
页码:173 / 181
页数:9
相关论文
共 21 条
[1]   Different strategies for formation of PEGylated EGF-conjugated PEI/DNA complexes for targeted gene delivery [J].
Blessing, T ;
Kursa, M ;
Holzhauser, R ;
Kircheis, R ;
Wagner, E .
BIOCONJUGATE CHEMISTRY, 2001, 12 (04) :529-537
[2]   A VERSATILE VECTOR FOR GENE AND OLIGONUCLEOTIDE TRANSFER INTO CELLS IN CULTURE AND IN-VIVO - POLYETHYLENIMINE [J].
BOUSSIF, O ;
LEZOUALCH, F ;
ZANTA, MA ;
MERGNY, MD ;
SCHERMAN, D ;
DEMENEIX, B ;
BEHR, JP .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (16) :7297-7301
[3]  
Erbacher P, 1999, J GENE MED, V1, P210
[4]   Nomenclature for synthetic gene delivery systems [J].
Felgner, PL ;
Barenholz, Y ;
Behr, JP ;
Cheng, SH ;
Cullis, P ;
Huang, L ;
Jessee, JA ;
Seymour, L ;
Szoka, F ;
Thierry, AR ;
Wagner, E ;
Wu, G .
HUMAN GENE THERAPY, 1997, 8 (05) :511-512
[5]   Water-soluble polyion complex associates of DNA and poly(ethylene glycol)-poly(L-lysine) block copolymer [J].
Katayose, S ;
Kataoka, K .
BIOCONJUGATE CHEMISTRY, 1997, 8 (05) :702-707
[6]   Intranasal gene delivery with a polyethylenimine-PEG conjugate [J].
Kichler, A ;
Chillon, M ;
Leborgne, C ;
Danos, O ;
Frisch, B .
JOURNAL OF CONTROLLED RELEASE, 2002, 81 (03) :379-388
[7]  
Kircheis R, 1999, J GENE MED, V1, P111
[8]   Tumor-targeted gene delivery of tumor necrosis factor-α induces tumor necrosis and tumor regression without systemic toxicity [J].
Kircheis, R ;
Ostermann, E ;
Wolschek, MF ;
Lichtenberger, C ;
Magin-Lachmann, C ;
Wightman, L ;
Kursa, M ;
Wagner, E .
CANCER GENE THERAPY, 2002, 9 (08) :673-680
[9]   Tumor-targeted gene delivery: an attractive strategy to use highly active effector molecules in cancer treatment [J].
Kircheis, R ;
Wightman, L ;
Kursa, M ;
Ostermann, E ;
Wagner, E .
GENE THERAPY, 2002, 9 (11) :731-735
[10]   Polyethylenimine/DNA complexes shielded by transferrin target gene expression to tumors after systemic application [J].
Kircheis, R ;
Wightman, L ;
Schreiber, A ;
Robitza, B ;
Rössler, V ;
Kursa, M ;
Wagner, E .
GENE THERAPY, 2001, 8 (01) :28-40